Evommune, Inc. Research and Development Expense
Evommune, Inc. (EVMN) reported Research and Development Expense of $26.41 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- Evommune, Inc. research and development expense for the quarter ending 2026-06-30 was $26.41M, a 34.49% increase year-over-year.
- Evommune, Inc. research and development expense for the quarter ending 2026-03-31 was $17.32M, a 20.59% increase year-over-year.
- Evommune, Inc. research and development expense for the quarter ending 2025-12-31 was $20.40M, a 14.42% increase year-over-year.
- Evommune, Inc. research and development expense for the quarter ending 2025-09-30 was $19.64M, a 47.78% increase year-over-year.
- Evommune, Inc. research and development expense for fiscal 2025 was $74.04M, a 15.25% increase from fiscal 2024.
- Evommune, Inc. research and development expense for fiscal 2024 was $64.24M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $26.41M 10-Q · filed 2026-08-06 | $43.73M 10-Q · filed 2026-08-06 | $64.13M derived: sum of 3 quarters · filed 2026-08-06 | $83.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $17.32M 10-Q · filed 2026-05-07 | $37.72M derived: sum of 2 quarters · filed 2026-05-07 | $57.36M derived: sum of 3 quarters · filed 2026-05-07 | $77.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $20.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $40.04M derived: sum of 2 quarters · filed 2026-03-05 | $59.68M derived: sum of 3 quarters · filed 2026-08-06 | $74.04M 10-K · filed 2026-03-05 |
| 2025-09-30 | $19.64M 10-Q · filed 2025-12-11 | $39.28M derived: sum of 2 quarters · filed 2026-08-06 | $53.64M 10-Q · filed 2025-12-11 | $71.47M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $19.64M 10-Q · filed 2026-08-06 | $34.00M 10-Q · filed 2026-08-06 | $51.83M derived: sum of 3 quarters · filed 2026-08-06 | $65.12M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $14.36M 10-Q · filed 2026-05-07 | $32.19M derived: sum of 2 quarters · filed 2026-05-07 | $45.48M derived: sum of 3 quarters · filed 2026-05-07 | |
| 2024-12-31 | $17.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $31.12M derived: sum of 2 quarters · filed 2026-03-05 | $64.24M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $13.29M 10-Q · filed 2025-12-11 | $46.41M 10-Q · filed 2025-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |